Rehmann Capital Advisory Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Rehmann Capital Advisory Group’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$20.1K	Sell	2,645 -1,460	-36%	-$10.9K	﹤0.01%	873
2019 Q2	$30.8K	Buy	4,105 +620	+18%	+$4.87K	﹤0.01%	1009
2019 Q1	$28.2K	Buy	3,485 +485	+16%	+$3.69K	﹤0.01%	1007
2018 Q4	$22.6K	Buy	3,000 +65	+2%	+$457	﹤0.01%	827
2018 Q3	$20.3K	Buy	2,935 +710	+32%	+$4.75K	﹤0.01%	1116
2018 Q2	$14.3K	Buy	2,225 +570	+34%	+$3.6K	﹤0.01%	1217
2018 Q1	$11K	Buy	+1,655	New	+$11.6K	﹤0.01%	1285

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Rehmann Capital Advisory Group's RDY Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Dr. Reddy's Laboratories (RDY) stake by 36% in Q3 2019, selling an estimated $10.9K and leaving 2,645 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Rehmann Capital Advisory Group first reported a position in RDY in Q1 2018 and has held it in 7 quarters since. The position peaked at $30.8K in Q2 2019. 152 funds tracked by Wall St. Rank hold RDY as of Q3 2019.

Rehmann Capital Advisory Group held 2,645 shares of Dr. Reddy's Laboratories worth $20.1K as of Q3 2019.
Rehmann Capital Advisory Group sold 1,460 Dr. Reddy's Laboratories shares in Q3 2019, an estimated $10.9K.
Dr. Reddy's Laboratories made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #873 holding.
Rehmann Capital Advisory Group first reported a position in Dr. Reddy's Laboratories in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Dr. Reddy's Laboratories position peaked at $30.8K in Q2 2019.
152 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.